Continuing versus new prescriptions for sedative-hypnotic medications: United States, 2005-2012

C.N. Kaufmann, A.P. Spira, C.A. Depp and R. Mojtabai

American Journal of Public Health, 2016, vol. 106, issue 11, 2019-2025

Abstract: Objectives.To assess trends in continuing and new prescriptions for sedative-hypnotic medications, including benzodiazepines (BZDs) and non-BZD receptor agonists (nBZRAs). Methods. Data came from the National Ambulatory Medical Care Survey and comprised 287 288 randomly sampled patient visits. Physicians reported medications prescribed and whether they were "continuing" or "new" prescriptions. We assessed trends in continuing BZD, new BZD, continuing nBZRA, and new nBZRA prescriptions from 2005 to 2012. Results. Proportions of visits with continuing prescriptions increased from 3.4% in 2005 to 4.7% in 2012 (P

Keywords: hypnotic sedative agent, adolescent; adult; age; aged; clinical practice; female; health care survey; human; male; medicine; middle aged; prescription; statistics and numerical data; United States; very elderly; young adult, Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Drug Prescriptions; Female; Health Care Surveys; Humans; Hypnotics and Sedatives; Male; Medicine; Middle Aged; Practice Patterns, Physicians'; United States; Young Adult (search for similar items in EconPapers)
Date: 2016
References: Add references at CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.2105/AJPH.2016.303382

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:aph:ajpbhl:10.2105/ajph.2016.303382_9

DOI: 10.2105/AJPH.2016.303382

Access Statistics for this article

American Journal of Public Health is currently edited by Alfredo Morabia

More articles in American Journal of Public Health from American Public Health Association
Bibliographic data for series maintained by Christopher F Baum ().